Comparison of dialysate- and plasma clearences between three different haemodialysis modes.

• Conditions: haemodialysis; treatment with artificial kidney; 10038430; 10038365

• Registration Number: NL-OMON31119
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Dialysis patients > 18 years of age.
Dialysis > 3 months.
Signed informed consent.
Uncomplicated hemodialysis.
AV fistula with flow > 350ml/min.
Residual function < 1 ml/min.
Hemoglobin level between 6.8 - 8.3 mmol/l.
No bleeding tendency.

Exclusion Criteria

Instable dialysis
No bleeding tendency.
No informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Dialysate samples: Samples collected: continuously and separated in aliquots<br /><br>every hour.<br /><br>Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin.<br /><br><br /><br>Blood samples:<br /><br>Before start treatment: Haemoglobin, Haematocrit, Albumin, CRP.<br /><br><br /><br>Before and during treatment: Samples collected: before treatment, every hour<br /><br>and at treatment end.<br /><br>Before artificial kidney and just before venous return. (i.e. after post<br /><br>dilution substitution)<br /><br>Phosphate, Cystatine C, Beta 2 Microglobuline, Vitamin B12, Urea, Creatinin,<br /><br>Albumin, Haematocrit.<br /><br><br /><br>Once every type of treatment: D-dimeer en TAT as measures of degree of clotting<br /><br>in the artificial kidney. Before and after treatment.<br /><br>Anti- Xa as measure of activity of Nadoparin. Before and after treatment.<br /><br>C3D as measure of complement activation. After treatment. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Diascan measurement on the Gambro AK 200-Ultra S. </p><br>